Instituto Alexander fleming

Buenos Aires CP 1426

3 studies enrolling now · 22 studies all time

What they study most

Advanced Gastrointestinal Stromal Tumors, B Cell Precursor Acute Lymphoblastic Leukemia, B-Cell Chronic Lymphocytic Leukemia, B-Cell Leukemia, Chronic, B-Lymphocytic Leukemia, Chronic, Breast Cancer, Breast Neoplasms, Cancer, Carcinoma, Non-Small-Cell Lung, Carcinoma, Non-small-cell Lung, Chronic Idiopathic Myelofibrosis, Chronic Lymphocytic Leukemia

Studies at this site

• RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive — Recruiting now
• A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer — Recruiting now
• (Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors — Recruiting now
• A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01) — Recruiting now
• Effects of Oncological Treatment During Pregnancy on Mother and Child — Recruiting now
• A Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin Compared to Rituximab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma — Running, not enrolling
• A Study of Valemetostat Tosylate Plus Pembrolizumab Versus Pembrolizumab Alone in First-Line NSCLC Without Actionable Genomic Alterations — Running, not enrolling
• A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer — Running, not enrolling
• Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07) — Running, not enrolling
• An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma — Running, not enrolling
• A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL — Running, not enrolling
• Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2) — Running, not enrolling
• A Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28) — Running, not enrolling
• Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer — Running, not enrolling
• A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer — Running, not enrolling
• A Study of Atezolizumab Versus Placebo as Adjuvant Therapy in Participants With High-risk Muscle-invasive Bladder Cancer (MIBC) Who Are ctDNA Positive Following Cystectomy — Running, not enrolling
• Safety of Pregnancy in BRCA Mutated Breast Cancer Patients — Completed
• A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors — Stopped early
• Gemcitabine With/Out Erlotinib in Unresectable Locally Advanced/Metastatic Pancreatic Cancer — Completed
• OSI-774 (Tarceva) Plus Gemcitabine in Patients With Locally Advanced, Unresectable or Metastatic Pancreatic Cancer. — Completed
• OSI-774 (Tarceva) in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer — Completed
• Satraplatin in Hormone Refractory Prostate Cancer Patients Previously Treated With One Cytotoxic Chemotherapy Regimen — Completed